These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10337463)

  • 1. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
    Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):90-2. PubMed ID: 10337463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.
    Bizzini B; Volpato I; Lachgar A; Cohen P; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):87-9. PubMed ID: 10337462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.
    Gringeri A; Santagostino E; Mannucci PM; Siracusano L; Marinoni A; Criscuolo M; Carcagno M; Fall LS; M'Bika JP; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):381-7. PubMed ID: 7580831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological effect of active anti-IFN alpha immunization in HIV-infected patients.
    Fall LS; M'Bika JP; Le Coq H; Fouchard M; Astgen A; Bizzini B; Gringeri A; Santagostino E; Burny A; Zagury D
    Biomed Pharmacother; 1995; 49(9):422-8. PubMed ID: 8746078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
    Gringeri A; Santagostino E; Cusini M; Muça-Perja M; Marinoni A; Mannucci PM; Burny A; Criscuolo M; Lu W; Andrieru JM; Mbika JP; Lachgar A; Fall LS; Chams V; Feldman M; Hermans P; Zagury JF; Bizzini B; Musicco M; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):55-67. PubMed ID: 8797687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.
    Coulaud IP; Gougeon ML; Gomard E; Descamps D; Lebon P; Aboulker JP; Bizzini B; Zagury D
    AIDS; 1997 Jun; 11(7):937-8. PubMed ID: 9189226
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.
    Stylianou E; Aukrust P; Bendtzen K; Müller F; Frøland SS
    Clin Exp Immunol; 2000 Mar; 119(3):479-85. PubMed ID: 10691920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy.
    Hejdeman B; Boström AC; Matsuda R; Calarota S; Lenkei R; Fredriksson EL; Sandström E; Bratt G; Wahren B
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):860-70. PubMed ID: 15320990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L;
    J Infect Dis; 2005 Aug; 192(4):607-17. PubMed ID: 16028129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
    Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR
    Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
    Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
    Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
    Goebel FD; Jablonowski H
    Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.